Ahmet Hazini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10475906/publications.pdf

Version: 2024-02-01

		1478505	1372567	
11	177	6	10	
papers	citations	h-index	g-index	
			1.00	
12	12	12	169	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas. Human Gene Therapy, 2021, 32, 216-230.	2.7	14
2	Tackling HLA Deficiencies Head on with Oncolytic Viruses. Cancers, 2021, 13, 719.	3.7	6
3	Coxsackievirus B3—Its Potential as an Oncolytic Virus. Viruses, 2021, 13, 718.	3.3	17
4	Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis. Journal of Molecular Medicine, 2021, 99, 1279-1291.	3.9	3
5	Deregulation of HLA-I in cancer and its central importance for immunotherapy. , 2021, 9, e002899.		73
6	Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H. Viruses, 2021, 13, 1918.	3.3	4
7	MiRâ€375â€mediated suppression of engineered coxsackievirus B3 in pancreatic cells. FEBS Letters, 2020, 594, 763-775.	2.8	9
8	Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. Cardiovascular Research, 2020, 116, 1756-1766.	3.8	16
9	New postmortem diagnostic biomarker for myocardial infarction: ischemia modified albumin. Australian Journal of Forensic Sciences, 2019, 51, 191-200.	1.2	2
10	Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma. Human Gene Therapy, 2018, 29, 1301-1314.	2.7	19
11	Investigation of ischemia modified albumin, oxidant and antioxidant markers in acute myocardial infarction. Postepy W Kardiologii Interwencyjnej, 2015, 4, 298-303.	0.2	14